During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

Brigham researchers have found that people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 ...

Drug Improves Effectiveness of Radiation for Lung Cancer That Has Spread to the ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial intelligence.

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among ...

JACKSON, Miss. (WJTV) – Registration is open for the University of Mississippi Medical Center (UMMC) Cancer Center and ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...